Clinical Trial Update: Safety and Efficacy Study of SYN115 in Parkinson's Patients Using Levodopa to Treat End of Dose Wearing Off [Phase 2, Phase 3]

View source ↗

Summary

A completed Phase 2/3 safety and efficacy study evaluated SYN115 added to levodopa in Parkinson's disease patients experiencing end-of-dose wearing-off.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• SYN115

Snippet

Sponsor: Biotie Therapies Inc. | Conditions: Parkinson's Disease | Phase 2, Phase 3 | Status: COMPLETED